Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Total Payables

Last Annual Value

698.82K

3-Year CAGR

3%

5-Year CAGR

-2%

10-Year CAGR

89%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Total Payables

NTRB · NASDAQ
CompanyTotal Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
698.82K
0.9%1.8%67.0% 
1.24M
-19.4%-6.8%N/A
1.57M
-23.5%-32.5%11.5%
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
1.61M
-14.7%-4.9%-9.6%
2.28M
-23.3%18.8%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
4.74M
21.8%7.7%N/A
868.12K
-14.1%9.1%N/A
5.76M
32.3%26.0%49.9%
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
21.50M
138.5%40.9%31.4%
IMA logo
ImageneBio Inc
NASDAQ:IMA
1.44M
-11.4%-9.6%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
10.14M
25.7%22.0%29.2%
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15